Isla-Mint 100-mg lozenges, No. 30 (10 x 3)
Ingredients
Active ingredient: aqueous extract of Iceland moss;
1 lozenge contains 100 mg of aqueous extract of Iceland moss ((2-4):1); solvent: water; contains a non-crystallizing sorbitol solution (1:2);
excipients: non-crystallizing sorbitol solution (E 420); aspartame (E 951), gum arabic, peppermint oil, copper complexes of chlorophylls (E 141), light mineral oil, purified water;
1 lozenge contains 0.385 g of carbohydrates, which corresponds to 0.03 bread units.
Dosage Form
Lozenge.
Main physical and chemical properties: flat, irregularly rounded, lens-shaped, green, gum-like lozenges with a peppermint flavor; the presence of air bubbles is permitted.
Pharmacotherapeutic group
Drugs used for throat disorders. ATC code R02A.
Pharmacological properties
Pharmacodynamics.
The drug contains an extract from the medicinal plant Cetraria islandica (Iceland moss), which is known for its therapeutic effect in inflammatory diseases of the respiratory tract.
The therapeutic effect of the drug in treating catarrhal diseases of the respiratory tract is based on the antimicrobial activity and immunostimulatory properties of the plant extract it contains, as proven by scientific research. The polysaccharides contained in the preparation coat the mucous membranes of the airways and effectively protect them from harmful external factors and various types of irritants. Since the medication also has protective properties, it can be used for preventive purposes, including during physical activity.
Prophylactic use of the medication can protect the mucous membranes and may reduce the respiratory tract’s susceptibility to infections. The medication does not irritate the stomach.
Pharmacokinetics. No data available.
Indications
Cough, including that associated with bronchitis; hoarseness (laryngitis, pharyngitis); bronchial asthma (as an adjunctive treatment). Excessive strain on the vocal cords (in singers, teachers, lecturers).
Dryness of the mucous membranes due to dry indoor air in living spaces or in insufficiently humidified office environments during the heating season, as well as with restricted nasal breathing or during physical activity.
Contraindications
Hypersensitivity to the active ingredient or other components of the medication.
Fructose intolerance.
Interactions with Other Medications and Other Types of Interactions
None known to date.
Special considerations for use
In patients with phenylketonuria, it should be noted that the medicinal product contains the sweetener aspartame (E 951).
If you have fructose intolerance, please note that this medication contains the sweetener sorbitol (E 420).
The herbal extracts contained in this medication may occasionally cause variations in its color and taste, which do not affect its therapeutic effect in any way.
Isla-Mint does not contain sugar and may therefore be prescribed to patients with diabetes.
1 lozenge corresponds to 0.03 bread units = 0.385 g of carbohydrates.
Use During Pregnancy or Breastfeeding.
No reports of adverse effects of the drug during pregnancy or breastfeeding have been received. However, no specific studies have been conducted in this patient population; therefore, the risk-benefit ratio should be weighed before using the drug.
Effect on reaction time when operating motor vehicles or other machinery.
If the drug is taken in accordance with these instructions, no adverse effects are expected.
Dosage and Administration
Adults and children 12 years of age and older should take 1 lozenge every hour (up to 12 lozenges per day); children aged 4 to 12 years should take 1 lozenge every 2 hours (up to 6 lozenges per day), allowing them to dissolve slowly in the mouth.
Isla-Mint can be used for an extended period.
Even after symptoms have subsided, Isla-Mint should be taken for several more days to achieve a lasting therapeutic effect.
If persistent symptoms do not improve within 4–5 days or, conversely, worsen, or if shortness of breath, fever, or purulent or bloody sputum occurs, consult a doctor immediately.
Children.
This medication is indicated for children 4 years of age and older, as the lozenges must be held in the mouth and allowed to dissolve slowly.
Overdose
No cases of overdose have been reported.
Side Effects
Allergic reactions may occur in rare cases.
Very rarely, the medication may have a laxative effect in sensitive patients, as it contains sorbitol.
Shelf Life
4 years.
Do not use after the expiration date printed on the package.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C, out of reach of children.
Packaging
10 lozenges per blister pack; 3 blister packs per cardboard box.
Dispensing Category
Over-the-counter.
Manufacturer
Engelhard Arzneimittel GmbH & Co. KG/
Engelhard Arzneimittel GmbH & Co. KG.
Address
Herzbergstrasse 3, 61138 Niederdorfelden, Germany/
Herzbergstrasse 3, 61138 Niederdorfelden, Germany.
Similar products
Products from the same category









